Blog Authors

Latest from Life Science IP

Apple Inc. v. Qualcomm Incorporated Docket No. 2020-1561, -1642 (IPR2018-01279, -01252) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1561.OPINION.4-7-2021_1759839.pdf) MOORE, REYNA, HUGHES April 7, 2021 Brief Summary:  Apple’s appeal of two IPR decisions dismissed for lack of standing in view of license agreement and speculative arguments related thereto. Summary:  Apple appealed IPR final written decisions (FWDs) holding Apple did show the challenged claims of US 7,844,037 and 8,683,362 obvious.  The litigation related to these patents between Apple and Qualcomm was settled, including a license, but Apple nevertheless appealed the FWDs.  Qualcomm argued waived standing to appeal “by failing to address, or submit evidence supporting, standing…
In re:  Board of Trustees of the Leland Stanford Junior University Docket No. 2020-1288 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1288.OPINION.3-25-2021_1753695.pdf) PROST, LOURIE, REYNA March 25, 2021 Brief Summary:  PTAB decision of ineligibility under section 101 of second Stanford patent application affirmed (“patent ineligible abstract ideas in the form of mathematical concepts”, “executing a mathematical algorithm on a regular computer”). Summary:  Stanford appealed PTAB decision affirming the final rejection of the claims as being “drawing to abstract mathematical calculations and statistical modeling, and similar subject that is not patent eligible” (“patent ineligible abstract mathematical algorithms and mental processes”).  The claims are to “computerized method…
Ethicon LLC v. Intuitive Surgical, Inc. Docket No. 2020-1600 (IPR2018-00936) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1600.OPINION.3-15-2021_1747758.pdf) (Non-Precedential) O’MALLEY, CLEVENGER, STOLL March 15, 2021 Brief Summary:  IPR finding of anticipation based on claim construction affirmed (e.g., negative limitation not supported); reversed and remanded as to proposed amended claims because Board “did not correctly identify the portions of Shelton I that Intuitive relied on”. Summary:  Ethicon appealed IPR FWD finding claims 1-14 of US 9,585,658 relating to surgical staplers invalid as anticipated and the denial of its motion to amend to substitute proposed claims 20-21.  The Board construed the terms “rotary drive member”, “rotary member”,…
Infinity Computer Products, Inc. v. OKI Data Americas, Inc. Docket No. 2020-1012 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1189.OPINION.2-10-2021_1730931.pdf) PROST, CLEVENGER, TARANTO February 10, 2021 Brief Summary:  DC indefiniteness determination affirmed due to “inconsistent prosecution history statements”. Summary:  Infinity appealed DC indefiniteness finding regarding US Pat. Nos. 6,984,811; 7,489,423; 8,040,574; and 8,294,915 directed to methods “of creating a scanning capability from a facsimile machine to a computer…via a passive link between” the two, “passive link” being the term found to be indefinite.  The FC panel explained that “[t]he term ‘passive link’ does not appear in the ‘811 patent specification” (‘811 being representative), and was…
Bayer Healthcare LLC v. Baxalta Inc. et al. and Nektar Therapeutics Docket No. 2019-2418, 2020-1017 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-2418.OPINION.3-1-2021_1740684.pdf) NEWMAN, LINN, STOLL March 1, 2021 Brief Summary:  DC claim construction, enablement, damages, and no willfulness findings affirmed. Summary:  Baxalta/Nektar (“B/N”) appealed DC denial of its motions for judgment as a matter of law (JMOL) or a new trial on infringement, enablement, damages ($155+ million), and its award of pre-verdict supplemental damages, regarding Bayer’s US 9,364,520 directed to recombinant “polypeptide conjugate[s]” of human factor VIII (FVIII) “covalently attached” through its B domain (one of six domains) to “one or more biocompatible polymers”…
John Bean Tech. Corp. v. Morris & Assoc., Inc. Docket No. 2020-1090, -1148 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1090.OPINION.2-19-2021_1736234.pdf) LOURIE, REYNA, WALLACH February 19, 2021 Brief Summary:  DC grant of intervening rights to Morris affirmed. Summary:  John Bean (JB) appealed DC decision as to equitable intervening rights and Morris cross-appeals the decision as to prosecution laches.  The dispute relates to JB’s US 6,397,622 covering an auger-type poultry chiller that issued on June 4, 2002.  On June 7, 2002, Morris wrote to JB “explaining its belief that the ‘622 patent was invalid and citing prior art to support its position” to which JB did…
Canfield Scientific, Inc. v. Melanoscan, LLC Docket No. 2019-1927 (IPR2017-02125) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1927.OPINION.2-18-2021_1735559.pdf) NEWMAN, DYK, REYNA February 18, 2021 Brief Summary:  Board IPR decision of no obviousness reversed as to independent claims and vacated the decision as to the dependent claims (e.g., ““[t]he Board did not discuss the dependent claims separately”). Summary:  Canfield appealed Board IPR decision finding it had not shown Melanoscan’s US 7,359,748 relating imaging devices “for the identification of maladies that effect human tissue” (e.g., skin) obvious in view of five references.  The FC panel considered the Board’s decision de novo (factual considerations for substantial evidence (Belden,…
Takeda Pharm. Co. et al. v. Torrent Pharm. Ltd., et al. Docket No. 2020-1552, -1598 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1552.OPINION.2-16-2021_1733600.pdf) (Non-Precedential) DYK, MAYER, CHEN February 16, 2021 Brief Summary:  DC holding that Torrent did not show Takeda’s claims related to algoliptin obvious affirmed. Summary:  Torrent appealed DC final judgment that Takeda’s US 7,807,689 “directed to alogliptin, a uracil-containing DPP-IV inhibitor useful for treating type II diabetes” was not proven by clear and convincing evidence to be invalid for obviousness or non-statutory obviousness-type double patenting.  The DC determined “a skilled artisan would not have been motivated to make Appellants’ proposed scaffold and isoteric…
Synchronoss Techs., Inc. v. Dropbox, Inc., Funambol, Inc. Docket No. 2020-2196, -2199 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-2196.OPINION.2-12-2021_1732513.pdf) PROST, REYNA, TARANTO February 12, 2021 Brief Summary:  DC claim construction, invalidity for indefiniteness, and grant of SJ affirmed. Summary:  Synchronoss appealed DC claim constructions and grant of summary judgment (SJ) finding all claims of US 6,671,757; 6,757,696; and 7,587,446 relating to systems for synchronizing data invalid under section 112, second paragraph (indefiniteness, “functional terms that do not impart any particular structure”) or not infringed.  Dropbox cross-appealed the DC’s decision that “the challenged claims, viewed as an ordered combination, impose sufficient limitations sufficient under Enfish…
M&K Holdings, Inc. v. Samsung Electronics Co., Ltd. Docket No. 2020-1160 (IPR2018-00696) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1160.OPINION.2-1-2021_1726200.pdf) MOORE, BRYSON, CHEN February 1, 2021 Brief Summary:  Board public accessibility finding affirmed; anticipation determination vacated and remanded for improper change in grounds from obviousness. Summary:  M&K appealed IPR final written decision (FWD) finding all claims of US 9,113,163 directed to methods for compressing video files.  M&K unsuccessfully argued to the Board that “none of the three references” used in Samsung’s arguments (WD4-v3, Park and Zhou) “were publicly accessibly, i.e., that interested parties could not have accessed any of those references by exercising reasonable diligence”…
Columbia University v. Illumina, Inc. Docket No. 2019-2302-5, -2452 (IPR2019-00291, -00318, -00322, -00385, -00797) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-2302.OPINION.2-1-2021_1726127.pdf) LOURIE, O’MALLEY, REYNA February 1, 2021 (Non-Precedential) Brief Summary:  IPR obviousness decisions affirmed (e.g., no teaching away). Summary:  Columbia appealed two IPR final written decisions (FWDs) holding claims 1 of US 9,718,852; 9,719,139; 9,708,358; 9,725,480; and claims 1-2 of US 9,868,985 directed to nucleotide analogs and methods for using those for DNA sequencing (“sequencing-by-synthesis” (SBS)) unpatentable as obvious in view of combinations of the Tsien, Prober, Metzker, and Dower references.  “This appeal centers on one aspect of the claims:  the use of a…
KeyNetik, Inc. v. Samsung Electronics Co., Ltd. Docket No. 2020-1271 (IPR2018-00986) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1271.OPINION.1-27-2021_1723945.pdf) DYK, CLEVENGER, O’MALLEY January 27, 2021 (Non-Precedential) Brief Summary:  IPR final written decision remanded for finding on reasonable expectation of success (“The Board erred in assigning no burden to Samsung and making no finding as to a reasonable expectation of success in combining the contested references.”) Summary:  KEYnetic appealed IPR final written decision (FWD) holding claims 1-20 of US 8,370,106 relating to motion detection systems unpatentable as obvious.  The FC panel affirmed the Board’s finding of a motivation to combine the prior art but remanded the…
Mylan Laboratories Limited v. Aventis Pharma S.A. Docket No. 2020-1302 (IPR2016-00712) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1302.RULE_36_JUDGMENT.1-15-2021_1718184.pdf) NEWMAN, O’MALLEY, WALLACH January 15, 2020 Brief Summary:  FC panel affirmed Board IPR FWD finding Sanofi’s amended claims not to be unpatentable for obviousness, public use and section 101. Summary:  FC panel affirmed Board final written decision (FWD) on remand that was entered on Oct. 22, 2019 (Sanofi Mature IP v. Mylan Labs., FC 2019 (vacating denial of Sanofi’s Motion to Amend (MTA) by introducing new replacement claims 31-34 and remanding)).  The FWD relates to US 8,927,592 directed to “[a] method of increasing survival comprising administering”…
SIMO Holdings Inc. v. Hong Kong uCloudlink et al. Docket No. 2019-2411 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-2411.OPINION.1-5-2021_1711937.pdf) O’MALLEY, WALLACH, TARANTO January 5, 2021 Brief Summary:  DC claim construction and grant of SJ to SIMO reversed due to improper interpretation of preamble language. Summary:  uCloud appealed DC claim construction, grant of summary judgment (SJ) of infringement, permanent injunction, and award of $8+ million in damages to SIMO.  The disputed patent, SIMO’s US 9,736,689, relates to systems for avoiding roaming charges of cellular networks.  uCloudlink’s accused products are devices that can act as WiFi hotspots.  The DC found the preamble of ‘689 claim 8…
General Electric Company v. Raytheon Technologies Corporation Docket No. 2019-1319 (IPR2017-00428) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1319.OPINION.12-28-2020_1707556.pdf) LOURIE, REYNA, HUGHES December 23, 2020 Brief Summary:  GE found to have standing due to a substantial risk of future infringement”; Board finding of no obviousness vacated and remanded (no teaching away; motivation to combine present). Summary:  GE appealed PTAB IPR decision finding the claims of Raytheon’s US 8,695,920 relating to methods “of designing a gas turbine engine” not invalid for obviousness.  The FC panel first found that GE had standing to appeal because it “alleged facts establishing that it is currently engaged in conduct creating…
Eli Lilly And Company v. Apotex, Inc. Docket No. 2020-1328 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1328.OPINION.12-21-2020_1705369.pdf) PROST, BRYSON, STOLL December 21, 2020 Non-precedential Brief Summary:  DC grant of SJ of infringement under DOE affirmed. Summary:  Apotex appealed DC grant of Lilly’s motion for summary judgment (SJ) of infringement of US 7,772,209 claiming methods of administering an antifolate, a particular methylmalonic acid lowering agent, and “an effective amount of pemetrexed disodium” (as in Lilly’s ALIMTA® product for mesothelioma and lung cancer) by Apotex’s ANDA, and that prosecution history estoppel (PHE) does not bar Lilly from asserting infringement under the doctrine of equivalents (DOE).  During…